問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

Division of Urology

Division of Nuclear Medicine

Division of Radiology

更新時間：2023-09-19

成佳憲Chen, Chia-Hsien
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

17Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

成佳憲

List

21Cases

2015-12-01 - 2028-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    JNJ-56021927

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-08-31 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma(ESCC)

  • Test Drug

    Durvalumab

Participate Sites
11Sites

Recruiting11Sites

2022-02-01 - 2028-01-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-10-01 - 2030-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-09-01 - 2026-08-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2013-01-01 - 2016-07-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-01-01 - 2020-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-03-01 - 2032-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

  • Condition/Disease

    Muscle-invasive Bladder Cancer (MIBC)

  • Test Drug

    Pembrolizumab (MK-3475) KEYTRUDA

Participate Sites
7Sites

Recruiting7Sites

2020-01-01 - 2029-12-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)、 Gastroesophageal Junction Carcinoma (GEJC)、 Esophageal Adenocarcinoma (EAC)

  • Test Drug

    Pembrolizumab (MK-3475) KEYTRUDA®

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB